A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors

NCT ID: NCT03844438

Last Updated: 2019-02-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-18
• Study Completion Date: 2022-03-01

Brief Summary

This study is a non-randomized, open, multiple administration and dose escalation phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetic/pharmacodynamics Characteristics of multiple oral administration of LPM3480226 in patients with advanced solid tumors., determine its dose-limiting toxicity and maximum tolerated dose, and initially observe its clinical effectiveness, and explore the metabolites in plasma after administration.

Detailed Description

The primary objective of this study was to assess the safety and tolerability of LPM3480226 tablets after oral administration to patients with advanced solid tumors, and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of LPM3480226.

A non-randomized, open, multiple dose escalation design was used with a total of five dose groups. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg , 200 mg , 400 mg , 600mg. Starting from the low-dose group, each subject received only one dose of the drug, and the next dose group study could only be performed if the previous dose group was completed and safe tolerance was confirmed.

Subjects were given the corresponding doses in the order，bid，28 days as a cycle, to evaluate the safety and tolerability of multiple doses. After confirming the safety and tolerance of the dose group in the first administration cycle, the administration was continued for another cycle according to the dose, and the subjects were evaluated for the efficacy after the two-cycle administration, and the subjects who did not have disease progression and is well tolerated and the investigator believes that continued treatment can benefit, the patient may continue to receive the dose of the drug on a voluntary basis, with a maximum dose of no more than one year.

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LPM3480226

LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.

Group Type: EXPERIMENTAL

LPM3480226

Intervention Type: DRUG

The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.

Interventions

LPM3480226

The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subject has voluntarily signed the written informed consent form (ICF)
• Male or female patients aged 18 to 75 years (18 years and 75 years are inclusive)
• Advanced solid tumors confirmed by histology or cytology (the following tumors may be preferred: melanoma, bladder cancer, kidney cancer, head and neck cancer, lung cancer, etc.);
• Standard treatment is ineffective, subjects refuse to accept or cannot tolerate standard treatment, or there is no standard effective treatment;
• The patient should have at least one measurable lesion as the target lesion (according to RECIST 1.1 criteria)
• The Eastern Cooperative Oncology Group (ECOG) performance status score is < 2 point.
• The predictable survival duration is ≥ 3 months
• Laboratory results during screening: absolute neutrophil count ≥ 1.5× 109/L; platelet count≥ 90× 109/L; hemoglobin≥ 90 g/L; Total bilirubin ≤1.5×upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5×ULN for the subjects without liver metastasis and ALT and AST< 5×ULN for the subjects with liver metastasis.; creatinine clearance ≥ 50 mL/min （Cockcroft-Gault formula)
• QTc interval male ≤ 450 ms female≤ 470 ms；
• The female subjects and male subjects of childbearing age and the partners of the male subjects agree to take reliable contraceptive measures during the study period and within 6 months after infusion of the study drugs

Exclusion Criteria

• There are any active autoimmune diseases or a history of autoimmune diseases [including but not limited to: rheumatoid arthritis, ankylosing spondylitis, autoimmune hemolytic anemia, interstitial pneumonia, uveitis, inflammation Intestinal disease, autoimmune hepatitis, autoimmune hypophysitis, glomerulonephritis, hyperthyroidism or decreased thyroid function (subclinical patients can be included), allergic asthma (where asthma in childhood has been completely relieved, and no intervention needed in adults can be included. Patients with asthma who need bronchodilators for medical intervention cannot be included.), and patients with vitiligo and type 1 diabetes can be included];
• Brain metastases, spinal cord compression, or cancerous meningitis, or brain CT or MRI scans confirmed brain metastases during screening period;
• have gastrointestinal diseases that may affect the absorption of the drug, or have undergone gastrointestinal surgery, which may affect the drug absorption by the investigator;
• Previously received radiotherapy, chemotherapy, surgery, or small molecule targeted therapy, less than 4 weeks prior to the first dose after treatment (if you had previously received nitrosourea or mitomycin chemotherapy, the time between the end of chemotherapy and the first dose Less than 6 weeks);
• Continue to use immunosuppressants (including but not limited to: tacrolimus, cyclosporine, etc.), systemic or topical hormonal therapy (dose > 10 mg / day prednisone or corresponding equivalent of other hormones)within 2 weeks prior to the first dose;
• Those who have received any vaccine within 28 days prior to the first dose;
• Any drug that affects tryptophan metabolism is used within 28 days prior to the first dose, including but not limited to: serotonin reuptake inhibitors (eg, fluoxetine, paroxetine, fluvoxamine, sertraline, Citalopram, escitalopram, etc.), tryptophan hydroxylase inhibitors (eg, trossostat ethyl ester, p-chlorophenylalanine, etc.);
• Those who have used CYP3A4 strong inducers or strong inhibitors within 2 weeks before the first dose or within 5 half-life periods (for long periods of time) (see Annex V);
• Immunological "checkpoint" inhibitors (including but not limited to: anti-PD-1/PD-L1/PD-L2 monoclonal antibodies, anti-CTLA-4 monoclonal antibodies) were used within 42 days prior to the first dose;
• A monoamine oxidase inhibitor or a drug having a monoamine oxidase inhibitory action (eg, pethidine hydrochloride, linezolid, methylene blue, etc.) is used 3 weeks before the first administration or within 5 half-life periods (for long periods of time);
• Interferon-treated within 6 months prior to the first dose;
• Those who have used IDO/TDO inhibitors in the past;
• Active infections;
• Any of Hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) or treponema pallidum antibody (TP-Ab) is positive;
• Those who received any other study drug or participated in another interventional clinical study 28 days before the first dose (42 days for mAbs);
• Other systemic anti-tumor therapists may be accepted during the study;
• Known to have a history of psychotropic substance abuse, alcohol abuse or drug abuse;
• Pregnant, lactating women or women with fertility test positive for pregnancy test;
• other important organ primary diseases (such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system or metabolic endocrine system disease) or other reasons which are considered by the investigator that the subject is unsuitable to be enrolled.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nanjing Bangnuo Biotechnology Co. Ltd

OTHER

Sponsor Role: collaborator

Luye Pharma Group Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Cancer Hospital

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Yuli Sun

Role: CONTACT

sunyuli@luye.com

010 5281 9375

Facility Contacts

Guo Jun

Role: primary

guoj307@126.com

010-88196348

References

Al-Zoubi RM, Elaarag M, Al-Qudimat AR, Al-Hurani EA, Fares ZE, Farhan A, Al-Zoubi SR, Khan A, Agouni A, Shkoor M, Bawadi H, Zakaria ZZ, Al Zoubi M, Alrumaihi K. IDO and TDO inhibitors in cancer immunotherapy: mechanisms, clinical development, and future directions. Front Pharmacol. 2025 Sep 16;16:1632446. doi: 10.3389/fphar.2025.1632446. eCollection 2025.

Reference Type: DERIVED

PMID: 41035912 (View on PubMed)

Other Identifiers

LY01013-CHN -101

Identifier Type: -

Identifier Source: org_study_id